- Home
- CGAU vs INVA Comparison
CGAU vs INVA Comparison
Compare CGAU & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- INVA
- Stock Information
- Founded
- CGAU 2002
- INVA 1996
- Country
- CGAU Canada
- INVA United States
- Employees
- CGAU N/A
- INVA N/A
- Industry
- CGAU Precious Metals
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- CGAU Basic Materials
- INVA Health Care
- Exchange
- CGAU Nasdaq
- INVA Nasdaq
- Market Cap
- CGAU 1.5B
- INVA 1.3B
- IPO Year
- CGAU N/A
- INVA 2004
- Fundamental
- Price
- CGAU $7.30
- INVA $19.07
- Analyst Decision
- CGAU Buy
- INVA Buy
- Analyst Count
- CGAU 2
- INVA 2
- Target Price
- CGAU $12.00
- INVA $40.50
- AVG Volume (30 Days)
- CGAU 934.6K
- INVA 1.0M
- Earning Date
- CGAU 08-06-2025
- INVA 07-30-2025
- Dividend Yield
- CGAU 2.74%
- INVA N/A
- EPS Growth
- CGAU N/A
- INVA N/A
- EPS
- CGAU 0.18
- INVA N/A
- Revenue
- CGAU $1,208,123,000.00
- INVA $369,844,000.00
- Revenue This Year
- CGAU N/A
- INVA $3.75
- Revenue Next Year
- CGAU $8.11
- INVA $12.62
- P/E Ratio
- CGAU $34.07
- INVA N/A
- Revenue Growth
- CGAU 2.88
- INVA 18.70
- 52 Week Low
- CGAU $5.41
- INVA $16.67
- 52 Week High
- CGAU $7.82
- INVA $22.00
- Technical
- Relative Strength Index (RSI)
- CGAU 53.60
- INVA 35.14
- Support Level
- CGAU $6.99
- INVA $18.92
- Resistance Level
- CGAU $7.54
- INVA $19.40
- Average True Range (ATR)
- CGAU 0.20
- INVA 0.56
- MACD
- CGAU -0.01
- INVA -0.21
- Stochastic Oscillator
- CGAU 62.50
- INVA 7.42
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.